The effect of dapagliflozin combined with sacubitril valsartan on inflammatory factors and prognostic factors in patients with heart failure after percutaneous coronary intervention therapy

CAI Tao; LAN Xiao-hong; SUN Lan-zhen; WEI Wei; WU Bo; YANG Yang

doi:10.3969/j.issn.1672-5301.2024.09.012

Abstract：Objective To analyze the effects of dagliflozin combined with sarcutrosovalsartan on inflammatory factors and soluble matrix lysin 2(sST 2),matrix metalloproteinase-9(MMP-M9),cystatin C(CysC)in patients with heart failure after percutaneous coronary intervention(PCI),and the effects of heart failure PCI.Methods 106 patients with heart failure after PCI surgery admitted to our hospital from January 2020 to January 2021 were selected as the research subjects.They were randomly divided into control and observation groups using a random number table method.The control group patients were treated with sacubitril valsartan,while the observation group was treated with dapagliflozin in addition to the control group.Conduct a two-year follow-up of all patients to compare the efficacy differences between the two treatment methods.Results There was no significant difference in cardiac function,serum inflammatory factors,and biochemical indicators of ventricular remodeling between the two groups of patients before treatment(P＞0.05),but after treatment,the left ventricular ejection fraction(LVEF)of the two groups of patients was higher than before treatment[(44.32±6.49)％vs.(52.56±7.27)％,(44.36±6.58)％vs.(48.03±6.14)％].After treatment,the LVEF level in the observation group was higher than that in the control group[(52.56±7.27)％vs.(48.03±6.14)％,P＜0.05];The left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),N-terminal B-type natriuretic peptide precursor(Nt-proBNP),serum inflammatory markers tumor necrosis factor-α(TNF-α),interleukin(IL)-1β,IL-6,high-sensitivity C-reactive protein(hs-CRP),sST2,MMP-9,and CysC levels were all lower than before treatment,and the observation group was lower than the control group(P＜0.05).One month after treatment,there was no significant difference in the 6-minute walk test(6MWT)between the two groups of patients(P＞0.05).3 and 6 months after treatment,the 6MWT of the observation group was higher than that of the control group(P＜0.05),and there was a difference within the group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of dapagliflozin and sacubitril/valsartan is more effective in treating heart failure patients after PCI compared to using sacubitril/valsartan alone.The effect is significant,and it improves the patient's heart function,reduces inflammatory reactions,and has high safety.